Vanguard Global Advisers’s Neurogene NGNE Stock Holding History

Vanguard Global Advisers’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$153K	Hold	4,854	–	–	﹤0.01%	2610
2026 Q1	$97.9K	Buy	+4,854	New	+$94K	﹤0.01%	2739

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Vanguard Global Advisers's NGNE Position: Q2 2026 in Review

Vanguard Global Advisers held its Neurogene (NGNE) position steady in Q2 2026 at 4,854 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #2610.

Vanguard Global Advisers first reported a position in NGNE in Q1 2026 and has held it in 2 quarters since. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

Vanguard Global Advisers held 4,854 shares of Neurogene worth $153K as of Q2 2026.
Vanguard Global Advisers left its Neurogene share count unchanged in Q2 2026.
Neurogene made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2610 holding.
Vanguard Global Advisers first reported a position in Neurogene in Q1 2026 and has held it in 2 quarters since.
112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.